Skip Nav Destination
Issues
15 July 2010
-
Cover Image
Cover Image
Transmission electron micrograph shows 100 nm lipid vesicles that contain a highly concentrated complex of arsenic trioxide (> 270 mmol/L). This nanoparticulate formulation (termed “nanobin”) markedly improves the pharmacokinetics of the cytotoxic agent, resulting in enhanced antitumor efficacy in a murine model of breast cancer. Nanobin encapsulation of arsenic trioxide may increase its therapeutic utility in breast cancer and potentially other solid tumors. For further details, please see the article by Ahn and colleagues on page 3607 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Molecular Pathways
Human Cancer Biology
Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
Neil R. Smith; Dawn Baker; Neil H. James; Kirsty Ratcliffe; Martin Jenkins; Susan E. Ashton; Graham Sproat; Ruth Swann; Neil Gray; Anderson Ryan; Juliane M. Jürgensmeier; Chris Womack
L1 Cell Adhesion Molecule Is a Novel Therapeutic Target in Intrahepatic Cholangiocarcinoma
Jeong-Ki Min; Jin-Man Kim; Shengjin Li; Jung Whoi Lee; Hyunho Yoon; Chun Jeih Ryu; Soung Hoo Jeon; Jae-Hyek Lee; Jin Young Kim; Hee Kwan Yoon; Young Kwan Lee; Bong-Hui Kim; Yeon Sung Son; Hong Seo Choi; Nam-Kyu Lim; Dae-Ghon Kim; Hyo Jeong Hong
Functional Mapping of Receptor Tyrosine Kinases in Myxoid Liposarcoma
Tiziana Negri; Emanuela Virdis; Silvia Brich; Fabio Bozzi; Elena Tamborini; Eva Tarantino; Genny Jocollè; Giuliana Cassinelli; Federica Grosso; Roberta Sanfilippo; Patrizia Casalini; Angela Greco; Marco A. Pierotti; Silvana Pilotti
Cancer Therapy: Preclinical
A Novel Nanoparticulate Formulation of Arsenic Trioxide with Enhanced Therapeutic Efficacy in a Murine Model of Breast Cancer
Richard W. Ahn; Feng Chen; Haimei Chen; Stephan T. Stern; Jeffrey D. Clogston; Anil K. Patri; Meera R. Raja; Elden P. Swindell; Vamsi Parimi; Vincent L. Cryns; Thomas V. O'Halloran
Angiopoietin-2 Interferes with Anti-VEGFR2–Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas
Sung-Suk Chae; Walid S. Kamoun; Christian T. Farrar; Nathaniel D. Kirkpatrick; Elisabeth Niemeyer; Annemarie M.A. de Graaf; A. Gregory Sorensen; Lance L. Munn; Rakesh K. Jain; Dai Fukumura
Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
Carol O'Brien; Jeffrey J. Wallin; Deepak Sampath; Debraj GuhaThakurta; Heidi Savage; Elizabeth A. Punnoose; Jane Guan; Leanne Berry; Wei Wei Prior; Lukas C. Amler; Marcia Belvin; Lori S. Friedman; Mark R. Lackner
Imaging, Diagnosis, Prognosis
High Levels of Nucleolar Expression of Nucleolin Are Associated with Better Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma
Lan Peng; John Liang; Hua Wang; Xianzhou Song; Asif Rashid; Henry F. Gomez; Lynda J. Corley; James L. Abbruzzese; Jason B. Fleming; Douglas B. Evans; Huamin Wang
Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features
Luisa M. Solis; Carmen Behrens; Wenli Dong; Milind Suraokar; Natalie C. Ozburn; Cesar A. Moran; Alejandro H. Corvalan; Shyam Biswal; Stephen G. Swisher; B. Nebiyou Bekele; John D. Minna; David J. Stewart; Ignacio I. Wistuba
Cancer Therapy: Clinical
A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors
Marwan G. Fakih; Gerald Fetterly; Merrill J. Egorin; Josephia R. Muindi; Igor Espinoza-Delgado; James A. Zwiebel; Alan Litwin; Julianne L. Holleran; Kangsheng Wang; Robert B. Diasio
Letter to the Editor
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.